Moelis & Company
Buying intent
84 tracked signals | Top 15 topics are below | Operations is carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Moelis & Company's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
6d ago
6d ago
2d ago
12d ago
16d ago
16d ago
12d ago
27d ago
4d ago
2d ago
19d ago
12d ago
2d ago
19d ago
23d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Moelis & Company
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
30 people across every department at Moelis & Company, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileMoelis & Company (“Moelis”) is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments, and financial sponsors. The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors. Moelis’s experien
New capability sought
Employee posts (LinkedIn)Financial Services; Sustainable Aviation Fuel; Asset Management; Capital Advisory; Capital Markets; Global Infrastructure Partners; Global Markets; Investment Banking
Top accounts researching Moelis & Company
names withheld on the public pageThese are companies whose own people brought up Moelis & Company unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
128 companies · 463 people are researching Deal Advisory
Moelis & Company's own team shows 18 signals on this topic. No one outside Moelis & Company has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Financial Advisor1,238 cos · 4,042 people
- Infrastructure5,287 cos · 14,524 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Leadership — 3 people
What's been said
public posts by Moelis & Company's teamNo public post naming Moelis & Company has surfaced in the past year, so this is what Moelis & Company's own team is posting about publicly — their topics, in their words.
Moelis is pleased to act as Exclusive Financial Advisor to the Big 12 Conference , a premier collegiate athletic association and media entity, on its strategic partnership with RedBird Development Group and investment from CAS. #DealAdvisory Link: https://bit.ly/3RLgQpO
May 2026Moelis is pleased to act as Exclusive Financial Advisor to the Big 12 Conference, a premier collegiate athletic association and media entity, on its strategic partnership with RedBird Development Group and investment from CAS. #DealAdvisory Link: https://bit.ly/4ug0ofC
May 2026Delayed but hardy thank you to @@AdWeek and @@3CVentures for putting together a great discussion.
May 2026Moelis acts as Exclusive Financial Advisor to MacroGenics, Inc. , a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, on the $122.5 million sale of its good manufacturing practice (GMP) drug substance manufacturing operations to Bora Pharmaceuticals . #DealAdvisory Press release: https://bit.ly/4dfyAkh
May 2026Moelis acts as Exclusive Financial Advisor to MacroGenics, Inc. , a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, on the $122.5 million sale of its good manufacturing practice (GMP) drug substance manufacturing operations to Bora Pharmaceuticals . #DealAdvisory Press release: https://bit.ly/4ttAZ0K
May 2026Congratulations to the team! Moelis was proud to join X-energy at Nasdaq to celebrate its IPO, where we served as lead joint bookrunner. Congratulations to the entire X-energy team on this significant milestone and the start of an exciting next chapter. https://bit.ly/4tusSSy
Apr 2026Moelis was proud to join X-energy at Nasdaq to celebrate its IPO, where we served as lead joint bookrunner. Congratulations to the entire X-energy team on this significant milestone and the start of an exciting next chapter. https://bit.ly/48mssVW
Apr 2026Strategic priorities
Earnings call; SEC filingsArtificial Intelligence; Artificial Intelligence Software
What changed recently
Earnings call; SEC filingsArtificial Intelligence; Artificial Intelligence Software